The fast pace of innovation in IT offers compelling investment opportunities
Truffle Capital is a pioneer investor in the exciting field of Energy
Biotechnology has radically transformed medicine over the past 25 years
Vexim, set up in 2006 as a spin-off from Teknimed, a French leader in orthopedic cements, specializes in minimally-invasive solutions for treatment of the causes and consequences of vertebral damage. It has notably developed the SpineJack® – a system for controlled anatomical repair of vertebral compression fractures (VCF).
Truffle initially invested in Vexim in 2006. Since then, Vexim has successfully treated hundreds of patients and obtained the CE mark for the SpineJack. Vexim was listed on Alternext in May 2012 (ALVXM).
Truffle Capital board members: Dr. Philippe Pouletty
Interview de Vincent Gardès, Directeur Général de Vexim sur le bilan 2014, l’évolution des produits et les perspectives, 24/03/2015 – La bourse et la vie.com
10 avril 2012 – Présentation de Vexim, spécialisée dans la chirurgie innovante du dos